Ascletis hits record high on weight loss drug's potential in early trial

Ascletis Pharma

13/08/2025 05:58

** Ascletis Pharma 1672.HK rises 9.7% to record high of HK$15.95; set for fifth straight session of gains

** Pharmaceutical products maker says its ASC47 shows greater efficacy with tirzepatide

** Notes pre-clinical data builds on evidence of ASC47's potential as important therapeutic approach to treat obesity

** Adds ASC47 low dose and tirzepatide combination shows 87% more relative weight loss vs tirzepatide monotherapy

** ASC47 is a muscle-preserving weight loss drug candidate for treatment of obesity

** YTD, stock surges 426.6%

 (Reporting by Donny Kwok)

 ((donny.kwok@thomsonreuters.com))